Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/II Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination With Systemic Anti-cancer Agents in Patients With ER Positive Breast Cancer or Advanced Solid Tumors

Next Previous
Trial Profile

A Phase Ib/II Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination With Systemic Anti-cancer Agents in Patients With ER Positive Breast Cancer or Advanced Solid Tumors

Status: Suspended
Phase of Trial: Phase I/II

Latest Information Update: 21 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lisaftoclax (Primary) ; Palbociclib (Primary)
  • Indications Advanced breast cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Ascentage Pharma

Most Recent Events

  • 19 Aug 2024 Status changed from recruiting to suspended due to company decision
  • 27 Nov 2023 Planned End Date changed from 1 Oct 2023 to 1 Oct 2024.
  • 27 Nov 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Jul 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top